1Coiffier B,Hiaoun C,Ketterer N,et al.Rituximab(anti-CD20 monoclonal antibody)for the treatment of paients with relaspsing or refractory aggressive lymphoma:a multicenter phase II study[J].Blood,1998,92(6):1927-1932.
2Haim N,Rosenblatt E,Wollner M,et al.Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone,etoposide,ifosfamide and cisplatin[J].Cancer Chemother Pharmacol,1992,30(3):243-244.
3Coleman M,Leonard J,Shuster M,et al.DICE(dexamethasone,ifosfamide,cisplatin,etoposide)infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma(NHL)[J].Eur J Haematol Suppl,2001,64(2):41-45.
6Messori A, Vaiani M, Trippoli S, et al. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma:meta-analysis of randomized studies comparing third generation regimens with CHOP [J]. Cancer, 2001,84(3): 303-307.
7Multani P, White CA, Grillo-Lopez A. Non-Hodgkin's lymphoma: review of conventional treatments [J]. Curr Pharm Biotechnol, 2001,2(4): 279-291.
8Laport GF, Williams SF. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma [J]. Semin Oncol, 1998,25(4) :503-517.
9Coiffier B. Effective immunocheotherapy for aggressive nonHodgkin's lymphoma [J]. Semin Oncol, 2004,31 (1 Suppl 2):7-11.
10Gisselbrecht C, Mounier N. Improing second-line therapy in aggressive non-Hodgkin's lymphoma [J]. Semin Oncol, 2004,31 (1 Suppl 2): 12-16.
